UK's Largest Drugmakers Report Higher Than Expected Profits Amid U.S. Pricing Policy Concerns
AstraZeneca and GSK both reported first-quarter core earnings that exceeded expectations, signaling a positive start to 2026. However, European pharmaceutical CEOs have expressed concerns that U.S. policies, such as Trump's MFN drug pricing, could lead to fewer new medicines being launched in Europe.
Topics: Corporate Leadership Drug Pricing Policy Earnings Beat Pharmaceutical Industry